Electron transfer mediators and other metabolites and cofactors in the treatment of mitochondrial dysfunction

Nutrition Reviews

Volumn 67, Issue 8, 2009, Pages 427-438

  Orsucci, Daniele ^a   Filosto, Massimiliano ^b   Siciliano, Gabriele ^a   Mancuso, Michelangelo ^a  

^a UNIVERSITY OF PISA   (Italy)

^b Neurological Institute of Brescia   (Italy)

Author keywords

Carnitine; Coenzyme Q10; Creatine; Idebenone; Lipoic acid

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; CARNITINE; CREATINE; DICHLOROACETIC ACID; DIMETHYLGLYCINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IDEBENONE; LEVACECARNINE; MENADIOL SODIUM PHOSPHATE; NICOTINAMIDE; PLACEBO; REACTIVE OXYGEN METABOLITE; RETINOL; RIBOFLAVIN; SUCCINIC ACID; THIAMINE; THIOCTIC ACID; UBIDECARENONE; WARFARIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BECKER MUSCULAR DYSTROPHY; CARNITINE DEFICIENCY; CELL ENERGY; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; CLINICAL TRIAL; DEGENERATIVE DISEASE; DIET SUPPLEMENTATION; DISEASE CLASSIFICATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA DAMAGE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MEGADOSE; DRUG PENETRATION; DRUG SAFETY; DRUG TRANSPORT; DRUG WITHDRAWAL; DUCHENNE MUSCULAR DYSTROPHY; FRIEDREICH ATAXIA; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HUMAN; HUNTINGTON CHOREA; HYPOGLYCEMIA; HYPOTENSION; KEARNS SAYRE SYNDROME; LACTIC ACIDOSIS; LEBER HEREDITARY OPTIC NEUROPATHY; MELAS SYNDROME; MERRF SYNDROME; MITOCHONDRIAL MYOPATHY; MITOCHONDRIAL RESPIRATION; MYALGIA; NONHUMAN; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; PARKINSON DISEASE; PERIPHERAL NEUROPATHY; PROGRESSIVE SUPRANUCLEAR PALSY; RESPIRATORY CHAIN; REVIEW; RHABDOMYOLYSIS; SUBSTITUTION THERAPY; UBIDECARENONE DEFICIENCY;

ACIDOSIS, LACTIC; ANIMALS; ANTIOXIDANTS; CARNITINE; CREATINE; DIETARY SUPPLEMENTS; ELECTRON TRANSPORT; HUMANS; MITOCHONDRIAL DISEASES; SUCCINIC ACID; THIOCTIC ACID; UBIQUINONE; VITAMIN B COMPLEX; VITAMINS;

EID: 77956509964     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1111/j.1753-4887.2009.00221.x     Document Type: Review

References (74)

1. DiMauro S, Schon EA. Mitochondrial respiratory-chain diseases. N Engl J Med. 2003;348: 2656-2668.
2. Noji H, Yoshida M. The rotary machine of the cell, ATP synthase. J Biol Chem. 2001;276:1665-1668. (Pubitemid 32109632)
3. Filosto M, Mancuso M. Mitochondrial diseases: a nosological update. Acta Neurol Scand. 2007;115:211-221.
4. Mancuso M, Coppede F, Migliore L, Siciliano G, Murri L. Mitochondrial dysfunction, oxidative stress and neurodegeneration. J Alzheimers Dis. 2006;10:59-73.
5. Genova ML, Pich MM, Bernacchia A, et al. The mitochondrial production of reactive oxygen species in relation to aging and pathology. Ann N Y Acad Sci. 2004;1011:86-100.
6. Weissman L, de Souza-Pinto NC, Stevnsner T, Bohr VA. DNA repair, mitochondria, and neurodegeneration. Neuroscience. 2007;145:1318-1329.
7. Haas RH, Parikh S, Falk MJ, et al. Mitochondrial disease: a practical approach for primary care physicians. Pediatrics. 2007;120:1326-1333.
8. Schaefer AM, McFarland R, Blakely EL, et al. Prevalence of mitochondrial DNA disease in adults. Ann Neurol. 2008;63:35-39.
9. Siciliano G, Volpi L, Piazza S, Ricci G, Mancuso M, Murri L. Functional diagnostics in mitochondrial diseases. Biosci Rep. 2007;27:53-67.
10. DiMauro S, Mancuso M. Mitochondrial diseases: therapeutic approaches. Biosci Rep. 2007;27:125-137.
11. Chinnery P, Majamaa K, Turnbull D, Thorburn D. Treatment for mitochondrial disorders. Cochrane Database Syst Rev. 1:CD004426.
12. Argov Z, Bank WJ, Maris J, et al. Treatment of mitochondrial myopathy due to complex III deficiency with vitamins K3 and C: A 31P-NMR followup study. Ann Neurol. 1986;19:598-602.
13. Dallner G, Sindelar PJ. Regulation of ubiquinone metabolism. Free Radic Biol Med. 2000;29:285-294.
14. 10 in statinsssociatedmyopathy - a systematic review. J AmColl Cardiol. 2007;49:2231-2237.
15. 10 during physical fatigue. Nutrition. 2008; 24:293-299.
16. 10. Am Fam Physician. 2005;72:1065-1070.
17. 10 treatment in mitochondrial encephalomyopathies. Short-term doubleblind, crossover study. Eur Neurol. 1997;37:212-218.
18. Naccarati A, Molinu S, Mancuso M, Siciliano G, Migliore L. Cytogenetic damage in peripheral lymphocytes of mitochondrial disease patients. Neurol Sci. 2000;21(Suppl):S963-S965.
19. 10 enrichment decreases oxidative DNA damage in human lymphocytes. Free Radic Biol Med. 1999;27:1027-1032.
20. 10 therapy. Mutagenesis. 2004;19:43-49.
21. 10 biosynthetic genes. J Clin Invest. 2007;117:587-589.
22. Mollet J, Giurgea I, Schlemmer D, et al. Prenyldiphosphate synthase, subunit 1 (PDSS1) and OH-benzoate polyprenyltransferase (COQ2) mutations in ubiquinone deficiency and oxidative phosphorylation disorders. J Clin Invest. 2007;117:765-772.
23. 10 deficiency due to decaprenyl diphosphate synthase subunit 2 (PDSS2) mutations. Am J Hum Genet. 2006;79:1125-1129.
24. 10 deficiency. Am J Hum Genet. 2006;78:345-349.
25. 10 deficiency is caused by mutations in the electron-transferring- flavoprotein dehydrogenase (ETFDH) gene. Brain. 2007;130:2037-2044.
26. Quinzii CM, Kattah AG, Naini A, et al. Coenzyme Q deficiency and cerebellar ataxia associated with an aprataxin mutation. Neurology. 2005;64:539-541.
27. 10 deficiencies in ataxia with oculomotor apraxia 1. Neurology. 2007;68:295-297.
28. Mollet J, Delahodde A, Serre V, et al. CABC1 gene mutations cause ubiquinone deficiency with cerebellar ataxia and seizures. Am J Hum Genet. 2008;82:623-630.
29. Rotig A, Mollet J, Rio M, Munnich A. Infantile and pediatric quinone deficiency diseases. Mitochondrion. 2007;7(Suppl): S112-S121.
30. 10 in the MPTP model of Parkinsonism. J Neurochem. 2008;104:1613-1621.
31. 10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002;59:1541-1550.
32. Storch A, Jost WH, Vieregge P, et al, for the German Coenzyme Q(10) Study Group. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol. 2007;64:938-944.
33. 10 and GPI-1485 in early Parkinson disease. Neurology. 2007;68:20-28.
34. 10 in ALS. Neurology. 2005; 65:1834-1836.
35. 10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord. 2008;23:942-949.
36. 10 in migraine prophylaxis: a randomized controlled trial. Neurology. 2005;64:713-715.
37. 10 deficiency and response to supplementation in pediatric and adolescent migraine. Headache. 2007;47:73-80.
38. 10 in the treatment of hypertension: a meta-analysis of the clinical trials. J Hum Hypertens. 2007;21:297-306.
39. Tonon C, Lodi R. Idebenone in Friedreich's ataxia. Expert Opin Pharmacother. 2008;9:2327-2337.
40. 10 and vitamin E therapy. Mitochondrion. 2007;7(Suppl):S127-S135.
41. Di Prospero NA, Baker A, Jeffries N, Fischbeck KH. Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial. Lancet Neurol. 2007;6:878-886.
42. Stephens FB, Constantin-Teodosiu D, Greenhaff PL. New insights concerning the role of carnitine in the regulation of fuel metabolism in skeletal muscle. J Physiol. 2007;581:431-444.
43. Kira Y, Nishikawa M, Ochi A, Sato E, Inoue M. L-carnitine suppresses the onset of neuromuscular degeneration and increases the life span of mice with familial amyotrophic lateral sclerosis. Brain Res. 2006;1070:206-214.
44. Stephens FB, Evans CE, Constantin-Teodosiu D, Greenhaff PL. Carbohydrate ingestion augments L-carnitine retention in humans. J Appl Physiol. 2006;102:1065-1070.
45. Beal MF. Bioenergetic approaches for neuroprotection in Parkinson's disease. Ann Neurol. 2003;53(Suppl):S39-S47.
46. Montgomery SA, Thal LJ, Amrein R. Meta-analysis of double blind randomized controlled clinical trials of acetyl-Lcarnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. Int Clin Psychopharmacol. 2003;18:61-71.
47. Kidd PM. Neurodegeneration from mitochondrial insufficiency: nutrients, stem cells, growth factors, and prospects for brain rebuilding using integrative management. Altern Med Rev. 2005;10:268-293.
48. Nezu J, Tamai I, Oku A, et al. Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nat Genet. 1999;21:91-94.
49. Tein I, De Vivo DC, Bierman F, et al. Impaired skin fibroblast carnitine uptake in primary systemic carnitine deficiency manifested by childhood carnitine-responsive cardiomyopathy. Pediatr Res. 1990;28:247-255.
50. Paddon-Jones D, Børsheim E, Wolfe RR. Potential ergogenic effects of arginine and creatine supplementation. J Nutr. 2004;134(Suppl):S2888-S2894.
51. Hultman E, Soderlund K, Timmons JA, Cederblad G, Greenhaff PL. Muscle creatine loading in men. J Appl Physiol. 1996;81:232-237.
52. Kuhl CK, Layer G, Träber F, Zierz S, Block W, Reiser M. Mitochondrial encephalomyopathy: correlation of P-31 exercise MR spectroscopy with clinical findings. Radiology. 1994;192:223-230.
53. Tarnopolsky MA, Roy BD, MacDonald JR. A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle Nerve. 1997;20:1502-1509.
54. Klopstock T, Querner V, Schmidt F, et al. A placebo-controlled crossover trial of creatine in mitochondrial diseases. Neurology. 2000;55:1748-1751.
55. Wyss M, Schulze A. Health implications of creatine: can oral creatine supplementation protect against neurological and atherosclerotic disease?. Neuroscience. 2002;112:243-260.
56. Tarnopolsky MA. Clinical use of creatine in neuromuscular and neurometabolic disorders. Subcell Biochem. 2007;46: 183-204.
57. Jeppesen TD, Schwartz M, Frederiksen AL, Wibrand F, Olsen DB, Vissing J. Muscle phenotype and mutation load in 51 persons with the 3243A>G mitochondrial DNA mutation. Arch Neurol. 2006;63:1701-1706.
58. Stacpoole PW. The pharmacology of dichloroacetate. Metabolism. 1989;38:1124-1144.
59. DeStefano N, Matthews PM, Ford B, Genge A, Karpati G, Arnold DL. Short-term dichloracetate treatment improves indices of cerebral metabolism in patients with mitochondrial disorders. Neurology. 1995;45:1193-1198.
60. Kaufmann P, Engelstad K,Wei Y, et al. Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology. 2006;66:324-330.
61. Michelakis ED, Webster L, Mackey JR. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer. 2008;99:989-994.
62. Liet JM, PellEtier V, Robinson BH, et al. The effect of shortterm dimethylglycine treatment on oxygen consumption in cytochrome oxidase deficiency: a doubleblind randomized crossover clinical trial. J Pediatr. 2003;142:62-66.
63. Hargreaves IP, Sheena Y, Land JM, Heales SJ. Glutathione deficiency in patients with mitochondrial disease: implications for pathogenesis and treatment. J Inherit Metab Dis. 2005;28:81-88.
64. Beal MF. Mitochondria take center stage in aging and neurodegeneration. Ann Neurol. 2005;58:495-505.
65. Migliore L, Fontana I, Colognato R, Coppede F, Siciliano G, Murri L. Searching for the role and the most suitable biomarkers of oxidative stress in Alzheimer's disease and in other neurodegenerative diseases. Neurobiol Aging. 2005;26:587-595.
66. Isaac MG, Quinn R, Tabet N. Vitamin E for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev. 2008;3:CD002854.
67. Orrell RW, Lane RJ, Ross M. A systematic review of antioxidant treatment for amyotrophic lateral sclerosis/motor neuron disease. Amyotroph Lateral Scler. 2008;9:195-211.
68. Bardia A, Tleyjeh IM, Cerhan JR, et al. Efficacy of antioxidant supplementation in reducing primary cancer incidence and mortality: systematic review and meta-analysis. Mayo Clin Proc. 2008;83:23-34.
69. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA. 2007;297:842-857.
70. Barbiroli B, Medori R, Tritschler HJ, et al. Lipoic (thioctic) acid increases brain energy availability and skeletal muscle performance as shown by in vivo 31P-MRS in a patient with mitochondrial cytopathy. J Neurol. 1995;242:472-477.
71. 10, and lipoic acid in mitochondrial disorders. Muscle Nerve. 2007; 35:235-242.
72. Burke DG, Chilibeck PD, Parise G, Tarnopolsky MA, Candow DG. Effect of alpha-lipoic acid combined with creatine monohydrate on human skeletal muscle creatine and phosphagen concentration. Int J Sport Nutr Exerc Metab. 2003;13:294-302.
73. Omar A, Johnson LN. Tetracycline delays ocular motility decline in chronic progressive external ophthalmoplegia. Neurology. 2007;68:1159-1160.
74. DiMauro S, Mancuso M, Naini A. Mitochondrial encephalomyopathies: therapeutic approach. Ann NY Acad Sci. 2004;1011:232-245.